oping products for similar uses; Rosetta's
dependence on collaborators; the ability to obtain coverage and payment
from health plans and payers for diagnostic and therapeutic products
applying Rosetta's technology and Rosetta's short operating history; as
well as those risks more fully discussed under "Key Information - Risk
Factors" in Rosetta's Annual Report on Form 20-F for the year ended
December 31, 2007 on file with the Securities and Exchange Commission. In
addition, any forward-looking statements represent Rosetta's views only as
of today and should not be relied upon as representing its views as of any
subsequent date. Rosetta does not assume any obligation to update any
forward-looking statements unless required by law.
CONSOLIDATED STATEMENTS OF OPERATIONS
U.S. dollars in thousands (except share and per share data)
Six months Three months
ended June 30, ended June 30,
2008 2007 2008 2007
Unaudited Unaudited
Operating expenses:
Research and development, net $ 4,571 $ 2,864 $ 2,182 $ 1,703
Marketing and business
development.... 945 787 434 412
General and
administrative............ 1,725 1,275 896 595
Operating
loss....................... 7,241 4,926 3,512 2,710
Financial expenses(income)
net........... 334 (655) 185 (455)
Net
loss......................... $ 7,575 $ 4,271 $ 3,697 $ 2,255
Basic and diluted net loss per
Ordinary share . $ 0.63 $ 0.41 $ 0.31 $ 0.19
Weighted average number of
Ordinary shares used to
compute basic and diluted
net los
'/>"/>
SOURCE Rosetta Genomics Ltd Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 Related biology technology :1.
Rosetta Genomics Announces Conference Call and Webcast of Second Quarter Financial Results2.
Rosetta Genomics Completes Acquisition of Parkway Clinical Laboratories Inc.3.
Rosetta Genomics to Present at Collins Stewart Fourth Annual Growth Conference4.
Rosetta Genomics Announces Plans to Recruit a New Chief Financial Officer5.
Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development6.
Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests7.
/C O R R E C T I O N -- Rosetta Genomics Ltd/8.
Rosetta Genomics Reports First Quarter 2008 Financial Results9.
Rosetta Genomics Announces Conference Call and Webcast of First Quarter Financial Results10.
Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate11.
Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference